Cygnus Technologies Revenue and Competitors
Estimated Revenue & Valuation
- Cygnus Technologies's estimated annual revenue is currently $11.9M per year.
- Cygnus Technologies's estimated revenue per employee is $155,000
Employee Data
- Cygnus Technologies has 77 Employees.
- Cygnus Technologies grew their employee count by 51% last year.
Cygnus Technologies's People
Name | Title | Email/Phone |
---|---|---|
1 | VP, Technical Marketing & Business Development | Reveal Email/Phone |
2 | VP Operations | Reveal Email/Phone |
3 | VP Research and Development | Reveal Email/Phone |
4 | Senior Director, R&D | Reveal Email/Phone |
5 | Associate Director, Chromatography and Mass Spectrometry | Reveal Email/Phone |
6 | Project Manager | Reveal Email/Phone |
7 | Project Manager | Reveal Email/Phone |
8 | Project Manager | Reveal Email/Phone |
9 | Senior Scientist | Reveal Email/Phone |
10 | Senior Scientist | Reveal Email/Phone |
Cygnus Technologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is Cygnus Technologies?
Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.
keywords:N/AN/A
Total Funding
77
Number of Employees
$11.9M
Revenue (est)
51%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.1M | 87 | 10% | N/A |
#2 | $23.3M | 93 | 27% | N/A |
#3 | $24.4M | 116 | 8% | N/A |
#4 | $39M | 120 | 9% | N/A |
#5 | $32.3M | 122 | 8% | N/A |